Icon (NASDAQ:ICLR) Reaches New 52-Week Low – Here’s What Happened

Icon Plc (NASDAQ:ICLR) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $90.00 and last traded at $75.0010, with a volume of 471306 shares. The stock had previously closed at $133.14.

Key Icon News

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Some analyst support remains — Leerink Partners reaffirmed a “market perform” rating and a $105 price target, providing a floor for some investors. Leerink note
• Neutral Sentiment: ICON issued a timing update saying it is delaying release of Q4 and full‑year 2025 earnings while the internal investigation continues — the announcement is procedural but keeps uncertainty elevated until results are filed. Company update
• Negative Sentiment: Multiple law firms have opened securities‑fraud investigations and are soliciting shareholders after ICON disclosed possible revenue‑recognition issues; that legal overhang amplifies downside risk and potential remediation costs. Glancy announcement
• Negative Sentiment: Market reaction has already been severe: the initial accounting‑probe disclosure produced a large intraday share collapse and prompted additional plaintiff firms (Hagens Berman, Rosen, Block & Leviton, Frank R. Cruz, Ademi, Holzer & Holzer, Johnson Fistel, etc.) to launch or publicize investigations, increasing litigation risk and potential settlement exposure. Hagens Berman note
• Negative Sentiment: ICON pulled its 2025 outlook amid the probe and signaled potential revenue‑recognition restatements, which elevates execution risk and clouds near‑term earnings visibility — a key reason analysts and investors moved to cut exposure. Seeking Alpha

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ICLR shares. Bank of America reissued an “underperform” rating and issued a $75.00 target price on shares of Icon in a research report on Thursday. Truist Financial reissued a “hold” rating and issued a $222.00 price objective (down from $231.00) on shares of Icon in a report on Thursday, January 8th. UBS Group set a $220.00 price objective on Icon in a research note on Friday, October 24th. Zacks Research upgraded Icon from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 25th. Finally, BMO Capital Markets reiterated a “market perform” rating and issued a $100.00 price target on shares of Icon in a report on Thursday. Five analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Icon has an average rating of “Hold” and a consensus target price of $173.40.

Icon Stock Performance

The firm has a fifty day moving average of $175.93 and a 200 day moving average of $174.94. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The stock has a market capitalization of $7.51 billion, a price-to-earnings ratio of 12.58, a price-to-earnings-growth ratio of 1.68 and a beta of 1.27.

Institutional Trading of Icon

A number of hedge funds have recently added to or reduced their stakes in the company. Private Trust Co. NA increased its holdings in Icon by 200.0% in the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after buying an additional 94 shares in the last quarter. Toth Financial Advisory Corp purchased a new position in shares of Icon in the 4th quarter valued at about $27,000. Ameriflex Group Inc. purchased a new position in shares of Icon in the 3rd quarter valued at about $33,000. Wilmington Savings Fund Society FSB raised its holdings in Icon by 153.4% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock worth $58,000 after purchasing an additional 201 shares during the period. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in Icon during the third quarter worth approximately $63,000. 95.61% of the stock is owned by hedge funds and other institutional investors.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.